Johnson & Johnson acquires Halda Therapeutics for $3 billion to strengthen its oncology portfolio, focusing on prostate ...
UnitedHealth Group appoints Dr. Scott Gottlieb to its board, enhancing leadership amongst a time in which the company looks ...
Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...
In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...
Jay Lalezari, CEO, CytoDyn, emphasizes how regulatory T cells play a crucial role in tumor progression by enabling cancers to ...
Artificial intelligence is a wildcard in the selection process, most profoundly in its agentic form. AI agents 2 will help ...
The FDA’s new Commissioner’s National Priority Voucher signals a transformative shift in U.S. drug review, tying accelerated approval to manufacturing readiness, domestic supply-chain strength, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback